Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : XOMA. Bull or Bear? -- Ignore unavailable to you. Want to Upgrade?

To: Robert S. who wrote (6702)	7/16/1998 11:13:00 PM
From: Robert K.	Read Replies (1) \| Respond to of 17367

Robert S> Take notes from Her and post your results here. My take on the sum, (Its zero if it doesnt work), my take is small sum cause weak patent position. They cant make it, cant and wont develop it. Cant beatem so join em. Good deal for us. No bpi competition.

To: Robert S. who wrote (6702)	7/19/1998 1:01:00 PM
From: Robert K.	Respond to of 17367

According to the current company Faq>>>>>>>>>>>>>>>>>>>>>>>> In trauma>How big is the market for this indication? How will you price the product? How much could XOMA earn in revenues from this indication? There is at present no effective treatment for infectious complications. A pharmacoeconomic analysis should take into account reduced patient time in ICU or hospital. Pricing will reflect these factors; we expect product revenues would be substantial. ÿ Above are xomas opinion and not mine.